Clinical Trial Update: A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports the completion and results posting for evaluating different doses of BI 655130 in adults with moderate-to-severe palmoplantar …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Palmoplantar Pustulosis

Drugs mentioned

• BI 655130

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Palmoplantar Pustulosis (PPP) | Phase 2 | Status: COMPLETED | Results posted: 2022-07-28